AIMS: To determine the pharmacokinetic profile of norelgestromin (NGMN) and ethinyloestradiol (EE) following application of the contraceptive patch, Evra/Ortho Evra, at each of four anatomic sites (abdomen, buttock, arm, and torso). METHODS:Thirty-seven healthy, nonpregnant women aged 20-45 years participated in this open-label, four-period crossover study. Subjects were randomized to one of four treatment (site of application) sequences. Each patch was worn for 7 days, with a 1 month washout between treatments. Blood samples were collected before and at various times up to 240 h after application of each patch. Serum samples were assayed for NGMN and EE by validated methods. RESULTS: The serum concentration reference ranges for NGMN and EE are 0.6-1.2 ng ml-1 and 25-75 pg ml-1, respectively, based on studies of the mean Cave of oral norgestimate 250 microg and EE 35 microg. For all application sites, mean concentrations of NGMN and EE remained within these ranges during the 7 day wear period. Absorption of NGMN and EE during patch application on the buttock, arm, and torso was equivalent. Absorption of NGMN and EE during patch application on the abdomen was approximately 20% less than observed for the other three sites, although mean serum concentrations were still within reference ranges. A previous study demonstrated therapeutic equivalence of patches worn on the abdomen vs other sites. CONCLUSIONS:Serum concentrations of NGMN and EE from the contraceptive patch remain within the reference ranges throughout the 7 day wear period, regardless of the site of application (abdomen, buttock, arm, or torso).
RCT Entities:
AIMS: To determine the pharmacokinetic profile of norelgestromin (NGMN) and ethinyloestradiol (EE) following application of the contraceptive patch, Evra/Ortho Evra, at each of four anatomic sites (abdomen, buttock, arm, and torso). METHODS: Thirty-seven healthy, nonpregnant women aged 20-45 years participated in this open-label, four-period crossover study. Subjects were randomized to one of four treatment (site of application) sequences. Each patch was worn for 7 days, with a 1 month washout between treatments. Blood samples were collected before and at various times up to 240 h after application of each patch. Serum samples were assayed for NGMN and EE by validated methods. RESULTS: The serum concentration reference ranges for NGMN and EE are 0.6-1.2 ng ml-1 and 25-75 pg ml-1, respectively, based on studies of the mean Cave of oral norgestimate 250 microg and EE 35 microg. For all application sites, mean concentrations of NGMN and EE remained within these ranges during the 7 day wear period. Absorption of NGMN and EE during patch application on the buttock, arm, and torso was equivalent. Absorption of NGMN and EE during patch application on the abdomen was approximately 20% less than observed for the other three sites, although mean serum concentrations were still within reference ranges. A previous study demonstrated therapeutic equivalence of patches worn on the abdomen vs other sites. CONCLUSIONS: Serum concentrations of NGMN and EE from the contraceptive patch remain within the reference ranges throughout the 7 day wear period, regardless of the site of application (abdomen, buttock, arm, or torso).
Authors: Richard Dittrich; Lamar Parker; Jeffrey B Rosen; Gary Shangold; George W Creasy; Alan C Fisher Journal: Am J Obstet Gynecol Date: 2002-01 Impact factor: 8.661
Authors: Ji Wu; Kalpana S Paudel; Caroline Strasinger; Dana Hammell; Audra L Stinchcomb; Bruce J Hinds Journal: Proc Natl Acad Sci U S A Date: 2010-06-14 Impact factor: 11.205
Authors: Matt S Anderson; William D Hanley; Allison R Moreau; Bo Jin; Frederick A Bieberdorf; James T Kost; Larissa A Wenning; Julie A Stone; John A Wagner; Marian Iwamoto Journal: Br J Clin Pharmacol Date: 2011-04 Impact factor: 4.335
Authors: Jesus Hernandez-Juarez; Ethel A Garcia-Latorre; Manuel Moreno-Hernandez; Jose Fernando Moran-Perez; Miguel Angel Rodriguez-Escobedo; Gerardo Cogque-Hernandez; Rubén Julián-Nacer; Xochitl Hernandez-Giron; Rosalia Palafox-Gomez; Irma Isordia-Salas; Abraham Majluf-Cruz Journal: Reprod Health Date: 2014-04-26 Impact factor: 3.223